Quick Dispatch:
Your select study semaglutide Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your select study semaglutide Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design ships.
Need Help?
Questions about select study semaglutide Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for select study semaglutide Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design in your area.
SELECT Trial
29.65
SELECT Cardiovascular Trial Information
22.90
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
23.42
Population‐level impact of semaglutide 2.4 mg in patients with obesity or overweight and cardiovascular disease: A modelling study based on the SELECT trial - Nanna - 2025 - Diabetes, Obesity and Metabolism
28.14
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design
21.36
SELECT: Semaglutide's Impact on CVD Events Emerges Quickly
25.55
AHA Late Breaking Science: Day 1 Highlights 🫀SELECT Trial: Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes ✓: ⬇️ 20% Risk of a composite of cardiovascular death ❤️, nonfatal myocardial infarction, or
25.60
